Arvinas
Bookmark
ShareArvinas is a company. It is in New Haven, the United States and its CEO is John G. Houston. It was founded in 2013 and is part of the Health Care sector, specifically in the Biotechnology industry.
Key facts
- city: New Haven
- state: CT
- country: United States
- employees: 280 people
- revenues: 65.4M $
- sector: Health Care
- industry: Biotechnology
- foundation year: 2013
- CEO: John G. Houston
- CEO approval: 84 %
- ESG score: Try Pro to see estimate
- environmental score (ESG): Try Pro to see estimate
- social score (ESG): Try Pro to see estimate
- governance score (ESG): Try Pro to see estimate
See more facts
Extract data
Download datasets about Arvinas:
Dataset of stocks from Arvinas:
Arvinas is one of the companies in Biotechnology, companies in Health Care, companies in New Haven, companies in the United States and 3,456,835 companies in our database.
Talking Points
- Protein Degradation with PROTAC | Arvinas
- Arvinas is a clinical-stage biotechnology company leading the way in targeted protein degradation therapeutics.
- A revolutionary approach to protein degradation therapeutics. https://t.co/fEc6SErnkS
- Leading the way in targeted protein degradation therapeutics | Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins.
- Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
